These benefits, along with a earlier report demonstrating that a little-molecule ACKR3 agonist CCX771 displays anxiolytic-like habits in mice,2 support the notion of focusing on ACKR3 as a novel method to modulate the opioid program, which could open new therapeutic avenues for opioid-associated